Sensitivity to cisplatin determined by the histoculture drug response assay and clinical response of endometrial cancer

M. Kanasugi, Daisuke Aoki, N. Suzuki, N. Susumu, S. Nakata, M. Horiuchi, Y. Udagawa, S. Nozawa

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

This study investigated the value of the in vitro histoculture drug response assay (HDRA) for predicting the efficacy of chemotherapy in patients with endometrial cancer. Specimens were obtained from 115 patients with endometrial cancer treated at Keio University Hospital between 1994 and 2002. Tumor fragments were cultured on collagen sponge gel with cisplatin for 7 days, and cell viability was assessed. The cutoff value of the 50% inhibitory concentration of cisplatin was set at 23 μg/mL. Sensitivity of stage III or IV disease to chemotherapy was investigated, and differences of 5-year progression-free survival between patients with sensitive and resistant tumors were evaluated by the Kaplan-Meier method. Tumors were evaluable in 93.0% of patients (107/115). Among 38 patients in stages III or IV, 23 received chemotherapy containing cisplatin. Seven sensitive tumors did not recur, while recurrence/progression occurred within 6 months in 8/16 patients with tumors showing low sensitivity. Among stages III and IV patients, there was a significant difference of 5-year progression-free survival (P < 0.05) between those with tumors showing high or low sensitivity. Accordingly, the HDRA may predict the efficacy of chemotherapy for endometrial cancer.

Original languageEnglish
Pages (from-to)409-415
Number of pages7
JournalInternational Journal of Gynecological Cancer
Volume16
Issue number1
DOIs
Publication statusPublished - 2006 Jan

Fingerprint

Endometrial Neoplasms
Cisplatin
Pharmaceutical Preparations
Drug Therapy
Neoplasms
Disease-Free Survival
Porifera
Inhibitory Concentration 50
Cell Survival
Collagen
Gels
Recurrence

Keywords

  • Cisplatin
  • Endometrial cancer
  • Histoculture drug response assay

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology
  • Cancer Research

Cite this

Sensitivity to cisplatin determined by the histoculture drug response assay and clinical response of endometrial cancer. / Kanasugi, M.; Aoki, Daisuke; Suzuki, N.; Susumu, N.; Nakata, S.; Horiuchi, M.; Udagawa, Y.; Nozawa, S.

In: International Journal of Gynecological Cancer, Vol. 16, No. 1, 01.2006, p. 409-415.

Research output: Contribution to journalArticle

Kanasugi, M. ; Aoki, Daisuke ; Suzuki, N. ; Susumu, N. ; Nakata, S. ; Horiuchi, M. ; Udagawa, Y. ; Nozawa, S. / Sensitivity to cisplatin determined by the histoculture drug response assay and clinical response of endometrial cancer. In: International Journal of Gynecological Cancer. 2006 ; Vol. 16, No. 1. pp. 409-415.
@article{894622eba8994acc8a3309e5e0450cb7,
title = "Sensitivity to cisplatin determined by the histoculture drug response assay and clinical response of endometrial cancer",
abstract = "This study investigated the value of the in vitro histoculture drug response assay (HDRA) for predicting the efficacy of chemotherapy in patients with endometrial cancer. Specimens were obtained from 115 patients with endometrial cancer treated at Keio University Hospital between 1994 and 2002. Tumor fragments were cultured on collagen sponge gel with cisplatin for 7 days, and cell viability was assessed. The cutoff value of the 50{\%} inhibitory concentration of cisplatin was set at 23 μg/mL. Sensitivity of stage III or IV disease to chemotherapy was investigated, and differences of 5-year progression-free survival between patients with sensitive and resistant tumors were evaluated by the Kaplan-Meier method. Tumors were evaluable in 93.0{\%} of patients (107/115). Among 38 patients in stages III or IV, 23 received chemotherapy containing cisplatin. Seven sensitive tumors did not recur, while recurrence/progression occurred within 6 months in 8/16 patients with tumors showing low sensitivity. Among stages III and IV patients, there was a significant difference of 5-year progression-free survival (P < 0.05) between those with tumors showing high or low sensitivity. Accordingly, the HDRA may predict the efficacy of chemotherapy for endometrial cancer.",
keywords = "Cisplatin, Endometrial cancer, Histoculture drug response assay",
author = "M. Kanasugi and Daisuke Aoki and N. Suzuki and N. Susumu and S. Nakata and M. Horiuchi and Y. Udagawa and S. Nozawa",
year = "2006",
month = "1",
doi = "10.1111/j.1525-1438.2006.00409.x",
language = "English",
volume = "16",
pages = "409--415",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Sensitivity to cisplatin determined by the histoculture drug response assay and clinical response of endometrial cancer

AU - Kanasugi, M.

AU - Aoki, Daisuke

AU - Suzuki, N.

AU - Susumu, N.

AU - Nakata, S.

AU - Horiuchi, M.

AU - Udagawa, Y.

AU - Nozawa, S.

PY - 2006/1

Y1 - 2006/1

N2 - This study investigated the value of the in vitro histoculture drug response assay (HDRA) for predicting the efficacy of chemotherapy in patients with endometrial cancer. Specimens were obtained from 115 patients with endometrial cancer treated at Keio University Hospital between 1994 and 2002. Tumor fragments were cultured on collagen sponge gel with cisplatin for 7 days, and cell viability was assessed. The cutoff value of the 50% inhibitory concentration of cisplatin was set at 23 μg/mL. Sensitivity of stage III or IV disease to chemotherapy was investigated, and differences of 5-year progression-free survival between patients with sensitive and resistant tumors were evaluated by the Kaplan-Meier method. Tumors were evaluable in 93.0% of patients (107/115). Among 38 patients in stages III or IV, 23 received chemotherapy containing cisplatin. Seven sensitive tumors did not recur, while recurrence/progression occurred within 6 months in 8/16 patients with tumors showing low sensitivity. Among stages III and IV patients, there was a significant difference of 5-year progression-free survival (P < 0.05) between those with tumors showing high or low sensitivity. Accordingly, the HDRA may predict the efficacy of chemotherapy for endometrial cancer.

AB - This study investigated the value of the in vitro histoculture drug response assay (HDRA) for predicting the efficacy of chemotherapy in patients with endometrial cancer. Specimens were obtained from 115 patients with endometrial cancer treated at Keio University Hospital between 1994 and 2002. Tumor fragments were cultured on collagen sponge gel with cisplatin for 7 days, and cell viability was assessed. The cutoff value of the 50% inhibitory concentration of cisplatin was set at 23 μg/mL. Sensitivity of stage III or IV disease to chemotherapy was investigated, and differences of 5-year progression-free survival between patients with sensitive and resistant tumors were evaluated by the Kaplan-Meier method. Tumors were evaluable in 93.0% of patients (107/115). Among 38 patients in stages III or IV, 23 received chemotherapy containing cisplatin. Seven sensitive tumors did not recur, while recurrence/progression occurred within 6 months in 8/16 patients with tumors showing low sensitivity. Among stages III and IV patients, there was a significant difference of 5-year progression-free survival (P < 0.05) between those with tumors showing high or low sensitivity. Accordingly, the HDRA may predict the efficacy of chemotherapy for endometrial cancer.

KW - Cisplatin

KW - Endometrial cancer

KW - Histoculture drug response assay

UR - http://www.scopus.com/inward/record.url?scp=33645340052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645340052&partnerID=8YFLogxK

U2 - 10.1111/j.1525-1438.2006.00409.x

DO - 10.1111/j.1525-1438.2006.00409.x

M3 - Article

VL - 16

SP - 409

EP - 415

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 1

ER -